Tvardi Therapeutics, Inc. — Form D
Tvardi Therapeutics, Inc. of HOUSTON, TX, a company, filed a Form D exempt-offering notice with the SEC on 2021-06-16. The offering totals $75.1M, of which $72.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-06-16
- Form: D
- Accession: 0001742947-21-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $75.1M
- Amount sold: $72.4M
- Remaining: $2.6M
- Investors: 32
- Date of first sale: 2021-06-03
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-403053
Issuer
- Name: Tvardi Therapeutics, Inc.
- CIK: 0001742947
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 2450 Holcombe Boulevard, HOUSTON, TX, 77021
- Phone: 832-413-1362
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Imran Alibhai | Director | Houston, TX |
| Wallace Hall | Director | Beaverton, OR |
| Jamie McNab | Director | Houston, TX |
| Sujal Shah | Director | BOSTON, MA |
| Michael Wyzga | Director | Boston, MA |
| Imran Alibhai | Executive Officer | Houston, TX |
| Ronald J DePinho | Director | Houston, TX |
| David J Tweardy | Director | Houston, TX |
| David J Tweardy | Executive Officer | Houston, TX |
Other filings by this issuer (2)
More